Development of an oral suspension containing dry extract of Aleurites moluccanus with anti-inflammatory activity  by Mac Donald, Richie et al.
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a  b  s  t  r  a  c  t
Aleurites  moluccanus  L. (Willd.),  Euphorbiaceae,  is  a  tree that  is  native  to  Indonesia  and  India.  Various
parts  of  this  tree  are  commonly  used  in traditional  medicine  to treat  pain,  fever,  inﬂammation,  hepati-
tis,  gastric  ulcer  and  other  ailments.  An oral  suspension  containing  dried  extract  of  A.  moluccanus  was
developed  and  in  vivo  anti-inﬂammatory  activity  was  evaluated.  Extract  100  and  50  mg/ml  loaded  oral
suspensions  were  prepared  using  different  suspending  agents.  The  formulations  were  analysed  by their
appearance,  pH,  density,  redispersion  time,  rate  of settling,  rheological  behaviour,  distribution  of particle
size and  zeta  potential.  The  dose  uniformity  was  determined  by measuring  the content  of total  phenolic
compounds  expressed  in  swertisin  by  a validated  HPLC  method,  as  well  as  the  dissolution  proﬁle.  The  sta-
bility of oral suspensions  was  analysed  in accelerated  studies  (40 ◦C  for 6 months).  The  anti-inﬂammatory
activity  was  analysed  using  an in  vivo paw  oedema  model.  The  taste  and  odour  of  the suspensions  were
shown  to be characteristic  of the  extract.  Carmellose  sodium  (CS; 0.5%)  and microcrystalline  cellulose  and
carmellose  sodium  mixture  (MCCS;  1%)  showed  better  physical  behaviour.  The  content  of  total  phenolic
compounds  was  1.6 mg/ml  and  approximately  100%  of  the  total  phenolic  compounds  dissolved  within
10  min.  During  the  stability  study, the formulations  were  approved  by their  physical–chemical  proper-
ties  and  were  shown  to lose  12–14%  of  total  phenolic  compounds  at 40 ◦C after  6 months.  Suspensions
containing  50  mg/ml  of  standardised  dried  extract  inhibited  around  35  ±  7.6%  of  paw oedema.  Formu-
lations  containing  CS  showed  more  anti-inﬂammatory  activity.  Suspensions  containing  dry  extract  of
A. moluccanus  were  successfully  obtained  and  showed  physical  and  physical–chemistry  properties  that
were  appropriate  and  characteristic  of this  dosage  form,  suitable  for administration  in  paediatric  and
elderly populations,  making  this  an  alternative  to  tablets.
©  2015  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Aleurites moluccanus L. (Willd.), Euphorbiaceae, is a tree popu-
arly known in Brazil as “nogueira-da-india” and as Kukui, Tuitui
nd Candlenut in other countries. This tree is originally from
ndonesia and India and is widespread in tropical regions (Duke,
991). Its use in traditional medicine is extensive. Various plant
arts including seeds, leaves, ﬂowers and bark are used in tra-
itional medicine. There are reports of the use of the crushed
eeds and toast for constipation, decoction of leaves in poultices for
eadache, fevers, ulcers, swollen joints, and gonorrhoea, the bark
∗ Corresponding author.
E-mail: rlucinda@univali.br (R.M. Lucinda-Silva).
http://dx.doi.org/10.1016/j.bjp.2015.06.011
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editorais used for bloody diarrhoea and ﬂowers and the sap of branches in
the treatment of oral Candidiasis (Dunfors et al., 2002).
Phytochemical studies of leaves allowed isolation of the com-
pounds swertisin (Meyre-Silva et al., 1997), the mixture of 
and -amyrin, -hentriacontane, the mixture of stigmasterol,
-sitosterol and campesterol (Meyre-Silva et al., 1998) and 2′′-O-
ramnosil swertisin (Meyre-Silva et al., 1999). Furthermore, three
minor ﬂavonoids, derived from swertisin (Cesca et al., 2012a), and
ﬁve megastigmanes (Silva et al., 2012), which might contribute to
the potent anti-nociceptive effect of this species, were described.
The analgesic effect of the plant may  be associated with the
GABAergic and oxidonitrergic system and not be inﬂuenced by
adrenergic, cholinergic, dopaminergic and opioid systems (Quintão
et al., 2012). The A. moluccanus dry extract showed a potential
anti-nociceptive effect in the inﬂammatory sensitisation model,
 Ltda. All rights reserved.
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sing different inducing agents such as carrageenan, CFA or PGE2,
n mice. This biological effect can be attributed to the 2′′-O-
amnosilswertisin and swertisin ﬂavonoids, since they also showed
ctivity in the tested models (Quintão et al., 2011). Semisolid prepa-
ations containing 0.5 and 1.0% of A. moluccanus leaves dry extract
ere developed and showed potential anti-inﬂammatory, anti-
ociceptive and wound healing activities in in vivo pharmacological
odels (Cesca et al., 2012b).
The leaves dry extract was obtained by spray-drying in the lab-
ratory and at an industrial scale, as this is a reproducible process
nd technological transformations do not change the pharmaco-
ogical properties of the medicinal plant (Quintão et al., 2011). The
ry extract was standardised using HPLC methodology employ-
ng swertisin and 2′′-O-ramnosilswertisin as markers (Cesca et al.,
012a).
Further to the use of the semisolid formulation for topical appli-
ation (Cesca et al., 2012b), coated tablets containing dry extract
or oral use have also been developed in our research group. As
he 250 and 500 mg  dried extract tablets are relatively large due to
he required load carrier, their use in children or elderly patients is
estricted. Thus, the present study aimed to developed oral suspen-
ions in which the A. moluccanus dried extract has a slightly soluble
raction but, during the spray drying process, includes the addition
f an insoluble excipient (colloidal silicon dioxide), which prevents
ncorporation into a solution dosage form. Also, instead of quanti-
ying only the two markers 2′′-O-ramnosilswertisin and swertisin,
n the present work, we  quantiﬁed the total phenolic compounds of
he extract, expressed in swertisin in view of measuring more com-
onents of the herbal matrix (besides the two mentioned markers,
lso the previously detected minor ﬂavonoids and other unknown
henolic compounds). The HPLC methodology was successfully val-
dated and applied for content uniformity and dissolution of the
ormulations. The suspensions were characterised and the in vivo
nti-inﬂammatory activity was performed to ensure that the tech-
ological process did not change the pharmacological properties of
he extract.
aterial and methods
aterial
Microcrystalline cellulose and carmellose sodium mixture
Avicel® RC 591) was purchased from FMC  Biopolymer (Philadel-
hia, USA), carmellose sodium was purchased from DEG (São Paulo,
razil); methanol and acetonitrile (HPLC grade) were obtained from
.T. Baker (Phillipsburg, New Jersey, USA), and water was  puriﬁed
sing Easy Pure equipment (Waltham, Massachusetts, USA). Sor-
itol and sucralose, pharmaceutical grade, were purchased from
ia Farma (São Paulo, Brazil). The swertisin isolated from A. moluc-
anus leaves with a purity of >95% (Quintão et al., 2011) was used
s a reference substance for the development and validation of the
PLC method. The other reagents were of analytical grade and used
s received, without any further puriﬁcation.
able 1
ormulations of oral suspensions of Aleurites moluccanus dry extract.
Batches I II III IV 
Dry extract (mg/ml) 100 100 100 100 
CSa (%) 1.0 1.0 0.5 0.5 
MCCSa (%) – – – – 
Sucralose (%) 0.1 0.1 0.1 0.1 
Na  benzoate (%) 0.1 0.1 0.1 0.1 
Sorbitol (%) 50 – 50 
Water qsp qsp qsp qsp 
a CS, carmellose sodium; MCCS, microcrystalline cellulose and carmellose sodium mixte Farmacognosia 26 (2016) 68–76 69
Herbal material
A voucher specimen of Aleurites moluccanus L. (Willd.), Euphor-
biaceae, collected in July 2007 in Tijucas (State of Santa Catarina,
Brazil) and identiﬁed by Prof. Dr. Ademir Reis (Department of
Botany/Santa Catarina Federal University, Florianópolis, Brazil),
was deposited at the Barbosa Rodrigues Herbarium (Itajaí, Brazil),
under number VC Filho 001.
Dry extract of A. moluccanus containing 2′′-O-ramnosilswertisin
and swertisin at concentrations of 3.0% and 0.4%, respectively
(Cesca et al., 2012a), was  prepared on an industrial scale (Cen-
troﬂora, Botucatu, Brazil) from dry leaves. The extract was  prepared
by maceration with a 1:10 drug:solvent ratio and 7:3 ethanol:water
as a solvent, for ﬁve days. After extraction, ﬁltration and concentra-
tion, the extract was  mixed with colloidal silicon dioxide and dried
for the spray-drying method using inlet and outlet temperatures of
165–180 ◦C and 70–80 ◦C, respectively. This extract was previously
characterised (Quintão et al., 2011).
Preparation of A. moluccanus suspensions
Suspensions containing 100 mg/ml  and 50 mg/ml dry extract of
A. moluccanus were prepared according to the formulations shown
in Table 1. The dry extract used was  prepared on an industrial scale
and containing colloidal silicon dioxide (approx. 25%) as dry adju-
vant. Initially, the suspensor vehicle was prepared using water or
water/sorbitol as a vehicle, CS and MCCS as the suspending agent,
sodium benzoate as the preservative and sucralose as a sweetener.
The dry extract was wet  and dispersed in the suspensor vehicle. The
suspensions were stored in amber glass bottles for future analysis.
Analysis of the organoleptic characteristics and pH
In the organoleptic characteristics analysis, colour, physical
aspects, odours and taste were observed by direct perception
and/or sensory experimentation.
The pH value of the formulations was  determined by direct read-
ing in a potentiometer at 23 ± 2 ◦C, which was  previously calibrated
in pH 4 and 7. The analysis was performed in triplicate.
Analysis of settling behaviour
The suspensions were homogenised and transferred into a gra-
duate cylinder and the volume of sediment was  observed after 1,
2, 4, 6, 8 and 24 h. The rates of settling, F, which is deﬁned as the
ratio of the ﬁnal settled volume Vu to the original volume Vo, was
calculated using Eq. (1) (Florence and Attwood, 2006). The assay
was performed in triplicate.
F = Vu (1)
Vo
The redispersion time was determined by manual stirring
according to Tagliari et al. (2009). Approximately 40 ml  of suspen-
sion was  stored in 60 ml  glass bottles (approximately two-thirds
V VI VII VIII IX X
100 100 100 100 50 50
– – – – 0.5 –
1.0 1.0 0.5 0.5 – 1.0
0.1 0.1 0.1 0.1 0.1 0.1
0.1 0.1 0.1 0.1 0.1 0.1
– 50 – 50 20 20
qsp qsp qsp qsp qsp qsp
ure.
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f the volume). After 24 h, the bottles were inverted to 180◦ and
he necessary time for homogenisation of the disperse phase was
bserved.
heological analysis
The rheological behaviour was performed in a rotational vis-
ometer (Haake VT550, Waltham, USA), at 25 ± 0.1 ◦C, using an SV
IN sensor with a shear rate increase of 6.5 to 100 s−1in 150 s, a
onstant shear rate of 100 s−1for 150 s and a shear rate decrease of
00–6.5 s−1 in 150 s. The rheological behaviour, viscosity average
nd thixotropy were assessed. The ﬂow behaviour index of pseudo-
lasticity was calculated using the Ostwald-de Waele model (Eq.
2)), where  is the shear stress (Pa),  is the shear rate (s−1), k is
he ﬂow consistency index (Pa sn) and n is the ﬂow behaviour index.
he analysis was performed in triplicate.
 = k.n (2)
ssay and content uniformity analyses
For HPLC analysis, a Phenomenex® C8 column
150 mm × 4.6 mm,  5 m)  was used, with acidiﬁed water (pH
.5, acetic acid) (solvent A) and acetonitrile (solvent B) as the
obile phase in the gradient method from 90:10 (A:B, v/v) (0 min)
o 75:25 (A:B, v/v) (27 min), to 90:10 (A:B, v/v) (30 min), and then
aintaining the latter for 35 min, at a ﬂow of 0.6 ml/min, 30 ◦C,
ith detection at 254 and 338 nm.
The total phenolic assay (TP) expressed in swertisin was  pre-
iously determined for the A. moluccanus reference dried extract,
sing the above HPLC methodology and the swertisin as standard.
rieﬂy, the sum of the selected peaks in the reference extract chro-
atogram was expressed in swertisin concentrations, taking into
ccount the area and potency of the swertisin standard. This stan-
ardised reference extract was further used as a reference solution
o quantify these markers in the formulations, as described below.
The assay of the suspensions containing 50 mg/ml  dry extract
ere determined by HPLC and calculated TP expressed in swertisin
sing equation 3, where AA and Ap are the sum of the integrated
reas of the peaks corresponding to compounds which absorb
t 254 nm (total phenolic) in the sample and reference solution,
espectively; Mp is the weight (mg) of A. moluccanus dry extract in
ry basis used to prepare the reference solution; Pot is the extract
otency (%) of the reference solution previously determined against
wertisin (3.21% TP) and DF is the dilution factor.
P (mg/ml) = AA.Mp.Pot
Ap.100
× DF (3)
After stirring for 10 min, 10 ml  of suspension was  transferred to
 250 ml  volumetric ﬂask using methanol and acidiﬁed water (pH
.5, acetic acid) 1:1 v/v as solvent, which was sonicated for 30 min,
esulting in the sample solution at a concentration of 2 mg/ml.
he solution was ﬁltered through a 0.45 m regenerated cellu-
ose membrane ﬁlter and analysed by HPLC. The reference solution
f dry extract, also at 2 mg/ml, was prepared using the procedure
escribed for the sample solution. At least six individual injections
f reference solution were performed to assess suitability, including
esolution between peaks (R > 1.0) and the sum of area repeatability
RSD < 2.0%).
For content uniformity determination, the suspensions were
aintained for 24 h in the stagnancy state, stirring for 10 s, followed
y sampling at 1 cm below the meniscus; these were then prepared
ccording to the method described for the total phenolic assay.
he assay was performed in ten different samples (Farmacopeia
rasileira, 2010).e Farmacognosia 26 (2016) 68–76
Dissolution proﬁle
The dissolution method was  developed using different media
(0.1 M HCl, acetate buffer solution at pH 4.5 and PBS buffer solu-
tion at pH 6.8) and stirring speeds (50, 75 and 100 rpm), using
paddle apparatus; the method was performed at 37 ◦C with a vo-
lume of 900 ml,  according to the British Pharmacopoeia (2008),
with small changes. The suspensions were stirred for 10 min  and
10 ml  of sample was collected using a syringe. The samples were
ﬁltered through paper and a 0.45 m membrane and quantiﬁed by
HPLC using 0.55 mg/ml  of extract solution as a reference.
Stability study of suspensions
The stability study was performed in triplicate with 50 mg/ml
suspensions using accelerated conditions (40 ◦C), according to
Anvisa (2005). The organoleptic characteristics, viscosity, redisper-
sion time, rate of settling, pH and TP content were evaluated at time
zero, 30, 90 and 180 days. Additionally, microbiological analyses
(Farmacopeia Brasileira, 2010), potential zeta (Zetasizer, Malvern)
and dissolution tests were performed at zero and 180 days.
Validation of analytical methods
The assay and dissolution methods were submitted to analytical
validation (ICH, 2005). For the validation of both methods (assay
and dissolution), the 50 mg/ml  suspension was used. The selectivity
of the method was realised by comparing chromatograms of the
sample, the solvent, the reference extract and the mobile phase to
detect any possible interference of the excipients or solvents. The
resolution of the peaks (swertisin and 2′′-O-ramnosil swertisin) was
also calculated.
For assay method validation, the linearity was  assessed by
analysis of TP content in an analytical curve elaborated with a
standard extract solution after a series of dilutions in the range
of 0.5–5.0 mg/ml  (with 2.0 mg/ml  being the target concentration).
Analysis of the analytical curve was  also repeated in the presence
of the suspension following the addition of 100 l in each level of
standard extract solution (spiked curve). The solutions were pre-
pared in triplicate, injected twice and monitored at 254 nm. The
relative standard deviations (RSD%) of the slope, intercept and the
correlation coefﬁcient (r) of the curves were calculated using Excel
5.0 software. The quantiﬁcation limit (LOQ) was determined from
the analytical curve (ICH, 2005).
The accuracy was determined by repeating the assay described
in Dissolution proﬁle section, adding known concentrations of stan-
dard extract solution in volumetric ﬂasks with a ﬁxed volume of
suspension (5 ml); ﬁnal concentrations were obtained for three lev-
els (low, medium and high), in triplicate. The recovery (%) was
calculated in each level, after discounting the assay of a sample
solution (5 ml)  without spiking.
The repeatability was determined by repeating the assay
described in Dissolution proﬁle section, six times on the same day
by the same analyst. For intermediate precision, the repeatability
was performed on two  additional days by two  different analysts.
The average and RSD% of TP content were calculated (ICH, 2005).
The robustness was  realised by changing the temperature (29,
30 and 31 ◦C) and ﬂow (0.5, 0.6 and 0.7 ml/min). The data were eval-
uated using a single factor analysis of variance (ANOVA) (p < 0.05).
The dissolution test was  validated following the methodology
described in the United States Pharmacopoeia (USP, 2012), by selec-
tivity, linearity, precision and accuracy analysis. The selectivity was
realised by comparing chromatograms of the sample, the solvent
(dissolution medium), the standard extract, the mobile phase and
placebo (suspension vehicle without extract) to detect any possible
interference of the excipients or solvents. The target concentration
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f 0.55 mg/ml  was chosen and the method linearity was veriﬁed in
he 0.2–0.8 mg/ml  of concentration range. The accuracy was deter-
ined on three levels of standard addition, totalling ﬁnal levels
f 0.432 mg/ml, 0.556 mg/ml  and 0.679 mg/ml, in triplicate. In each
ube, 5 ml  of suspension was added. The recovery (%) was  calculated
or each level, after discounting the average TP content dissolved
n the cube without spiking. The precision of the method was eval-
ated by calculating the average and RSD% in the repeatability
nd intermediate precision. The repeatability was  determined by
epeating the dissolution test six times on the same day by the same
nalyst. For intermediate precision, the repeatability was repeated
n one additional day.
harmacological study
nimals
Male Swiss mice (25–35 g, ten weeks of age; n = 6 per group),
btained from the University of Vale do Itajaí (Itajaí, Brazil), were
sed in this study. The animals were maintained under condi-
ions of optimum temperature, light and humidity (22 ± 1 ◦C, 12 h
ight/dark cycle, 60–80% humidity) with water and food provided
d libitum.  All procedures used in this study followed recom-
endations of the Principles of Laboratory Animal Care guide from
ational Institutes of Health (NIH) publication no. 85-23, and were
pproved by the Univali Animal Ethics Committee (Protocol num-
ers 416/2008). Every effort was made to minimise animal suffering
nd reduce the number of animals used.
arrageenan-induced paw oedema
The experiments were conducted in accordance to Tratsk et al.
1997) with some modiﬁcations. The animals received injections
ontaining 50 l of Carrageenan (0.3 mg/paw) under the surface of
he right hind-paw. The other hind-paw received NaCl solution and
as used as a control. The mice were pre-treated with the formula-
ions (250 mg/kg, p.o.) or with the suspensor vehicle 1 h before the
arrageenan injection. Indomethacin (10 mg/kg, p.o.) was  used as
 positive control. The oedema induced by carrageenan was  evalu-
ted 0.5, 1, 2, 4, 6 and 24 h after the injection and expressed in l
omparing the differences between the right and left hind-paws.
tatistical analyses
The results were expressed as mean ± standard error of the
ean (E.P.M. 95%). The percentage of the inhibition was shown
sing mean ± standard error of the average of the difference (in
ercentage) between the areas under the curve (AUC) in relation to
he control group. The statistical analyses of the data obtained were
xpressed using two-way analysis of variance (ANOVA) followed
able 2
esults of pH value and settling and rheological behaviours of suspensions containing Ale
Batches pH Rate of settlinga (%) Sediment characteristic Sup
char
I 5.10 ± 0.02 49.67 ± 0.03 Compact +
II  4.56 ± 0.02 98.00 ± 0.03 Loose +
III  4.77 ± 0.01 40.00 ± 0.07 Loose +
IV  4.82 ± 0.02 83.66 ± 0.06 Loose +
V  5.06 ± 0.01 39.66 ± 0.00 Loose +
VI  4.46 ± 0.00 75.66 ± 0.02 Loose +
VII  4.81 ± 0.00 25.66 ± 0.00 Loose +
VIII  4.83 ± 0.01 39.00 ± 0.06 Loose +
IX  5.17 ± 0.03 ndb Compact +
X  5.08 ± 0.03 33.00 ± 0.04 Loose +
a Rate of settling after 8 h.
b It did not observed the sediment formation.
c + cloudy; ++ less cloudy; +++ clear.
d Index of ﬂow behaviour.e Farmacognosia 26 (2016) 68–76 71
by Bonferroni test, using one-way ANOVA followed by Dunnet or
Newman-Keuls, or using the Student T test when suitable.
Results and discussion
To develop a new anti-inﬂammatory and analgesic herbal
medicine from the dry extract of A. moluccanus leaves, tablets
containing dry extract (250 and 500 mg)  for oral administration
(unpublished data) and also semisolid dosage form containing 0.5%
and 1% dry extract were initially prepared (Cesca et al., 2012b). In
search of an alternative to oral administration, in the present study,
the dry extract was incorporated in the oral suspension due to its
partial solubility in aqueous vehicle.
The A. moluccanus dry extract used in the present study
was obtained on an industrial scale in the form of a pow-
der with agglomerated and smooth particles, a greenish brown
colour and characteristic odour. The average particle size was
129.388 ± 62.907 m,  moisture content was  4.04 ± 0.05% (Quintão
et al., 2011) and the speciﬁcation of total phenolic content
expressed in swertisin is 3.04–3.72%.
Development of oral suspensions
In the suspensions development, besides the suspending agents
used in the formulations shown in Table 1, xanthan gum, hypromel-
lose and methylcellulose were also evaluated as viscosity agents,
but were rejected due to the unfavourable organoleptic aspects
obtained. Therefore, characterisation analyses were conducted for
formulations I at X containing CS and MCCS. The suspensions
showed ﬂavour and colour characteristics of dry extract, i.e.,  green-
ish brown, not bitter in taste, agreeable odour, and homogeneous
dispersion of extract in the vehicle.
The formulations showed a pH value of 4.46 at 5.17 (Table 2). The
use of different suspending agents did not result in any signiﬁcant
changes in this property. The suspensions containing only water as
vehicle (batches I, III, V and VII) had lower sediment volumes and
also higher settling rates (Table 2 and Fig. 1). The sorbitol addition
in the vehicle increased the sediment volume and the settling rate
decreased, probably due to the increased viscosity provided by this
vehicle.
The sediment of formulations was  classiﬁed as ﬂocculated or
unﬂocculated from the data of the rate of settling after resting for
8 h, the sediment characteristics (loose or compact) and the aspect
of the supernatant (cloudy or clear). The suspending agents used
resulted in suspensions with smaller sediment volume, but which
was kept loose. The formulation containing 0.5% CS had slower
and more compact sediment than the formulation with 1% MCCS
(Table 2). The suspensions showed redispersion times of less than
urites moluccanus dry extract.
ernatant
acteristicc
Resuspension (min) Viscosity (mPas s) nd
 0.28 ± 0.02 35.67 ± 2.13 0.74 ± 0.03
+ 0.28 ± 0.02 44.28 ± 3.69 0.63 ± 0.71
++ 0.19 ± 0.01 25.83 ± 3.69 0.19 ± 0.02
++ 0.33 ± 0.02 38.13 ± 2.13 0.98 ± 0.10
+ 0.06 ± 0.01 38.13 ± 2.13 0.18 ± 0.02
+ 0.10 ± 0.02 44.28 ± 3.69 0.20 ± 0.07
+ 0.08 ± 0.01 38.13 ± 2.13 0.25 ± 0.02
++ 0.10 ± 0.01 18.45 ± 0.00 0.63 ± 0.02
 0.61 ± 0.02 53.20 ± 1.99 0.91 ± 0.08
+ 0.05 ± 0.00 6.45 ± 0.18 0.24 ± 0.02
72 R. Mac Donald et al. / Revista Brasileira d
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Fig. 1. Settling behaviour of suspensions containing dry extract of Aleurites moluc-
c
c
3
a
v
t
t
a
IX and X. The suspensions showed colour, odour and ﬂavour cha-anus with different suspending agents. (A) Croscarmellose sodium; (B) mixture of
armellose sodium + cellulose; (C) sorbitol 20%.
0 s (Table 2). The behaviour was dependent on the suspending
gent and vehicle. The formulations with MCCS and only water as
ehicle showed the shortest redispersion time, which is related to
he type of sediment formed.The average viscosity of the suspensions was dependent upon
he type and concentration of the suspending agent and vehicle. The
ddition of sorbitol as a carrier replacing part of the water (50%)e Farmacognosia 26 (2016) 68–76
increased the viscosity of the formulations. These results have a
direct relationship on the rate of settling and may  have also inﬂu-
enced the redispersion time.
The suspensions exhibited non-Newtonian rheological
behaviour, i.e.,  a reduction of viscosity with increasing shear
rate (). Materials with non-Newtonian behaviour may  exhibit
plastic (n = 1), pseudo-plastic (n < 1) and dilatant (n > 1) ﬂow. To
determine the ﬂow type, in this study, we used the Ostwald-de
Waele’s mathematical model. As shown in Table 2, the suspensions
have n value smaller than 1, therefore they have a pseudo-plastic
ﬂow-type.
The A. moluccanus suspensions showed different ﬂow behaviour
in the ascendant and down rheological curves. The thixotropic
(positive thixotropy) or anti-thixotropic (negative thixotropy)
behaviour was determined by quantifying the area between the
upward and downward curves (Nutan and Reddy, 2010). This
occurrence may  be explained as a result of the increasing colli-
sion frequency of the dispersed particles or polymeric molecules
in suspension, resulting in increased interparticle bonds over time
(Martin, 2006). The rheological behaviour of the suspensions is
expected for herbal suspensions in pharmaceutical use. They are
prepared with sufﬁcient viscosity to maintain the dispersed parti-
cles for a suitable time interval necessary for the administration of
the medicine and reduced viscosity when shaken, allowing better
homogenisation of the settled powder.
The total phenolic content expressed in the swertisin ave-
rage assay and content uniformity of the IX and X formulations
were determined by HPLC, being 103.3 ± 0.69% and 107.4 ± 0.40%,
respectively. The recommended range of total phenolic compounds
is 90–110%; therefore, the suspensions are according to speciﬁca-
tions. The RSD% was less than 2%, which is relevant because the
dosage form is a heterogeneous system and is a phytoderivative.
Dose uniformity is a recommended test for pharmaceutical
suspension assessment; thus, the content uniformity was per-
formed to IX and X formulations. The total phenolic assay was
determined with ten doses of suspension resulting in a con-
tent of 1.67 mg/ml  ± 0.03 (RSD% = 2.18%) and 1.68 mg/ml ± 0.004
(RSD% = 0.28%) for IX and X suspensions, respectively. RSD% va-
lues less than 3% expressed the dose uniformity of suspensions and
the safety of the drug.
For analysis of the dissolution proﬁle and the dissolution test,
suspensions of A. moluccanus were initially tested using different
analyses, with the following variables being explored: dissolution
medium (HCl buffer, pH 4.5 acetate buffer and pH 6.8 phosphate
buffer), and stirring speed (50, 75, and 100 rpm).
The dissolution proﬁles obtained under different conditions
of dissolution analysis showed that more than 80% of the total
phenolic dissolved in the ﬁrst three min  of analysis (Fig. 2). We
observed a higher dissolution rate in a simulated gastric environ-
ment (0.1 M HCl) and pH 4.5 acetate buffer in comparison to pH 6.8
phosphate buffer; thus, the acetate buffer was chosen as the disso-
lution medium. These results are in agreement with the dissolution
medium selected for A. moluccanus tablets analysis (unpublished
data). A weak inﬂuence of the stirring rate was  observed on the pro-
portion of dissolved phenolic compounds (Fig. 2) and there was no
direct correlation between them. The speed of 75 rpm was  chosen
for further study.
Stability of suspensions
The stability study of suspensions was carried out with batchesracteristics that were unchanged after 180 days of storage at 40 ◦C.
At time zero, and throughout the stability study, the suspensions
showed a pH value of about 5.0 (Table 3). Although the change
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Table  3
Results of accelerated and long time stability study of Aleurites moluccanus suspension.
Analysis Batches
IX X
t0 t180 t0 t180
30 ◦C (long time study)
pH 5.17 ± 0.03 5.03 ± 0.01 5.08 ± 0.03 4.93 ± 0.11
Redispersion time (s) 36.77 ± 1.26 11.33 ± 1.52 3.16 ± 0.23 2.60 ± 0.57
Viscosity (mPa s) 53.20 ± 1.99 20.5 ± 1.42 6.45 ± 0.18 3.69 ± 0.0
Zeta  potential -33.90 ± -33.90 -41 ± 4.12 -33.5 ± 5.79 -35.1 ± 5.77
TPa (mg/ml) 1.70 ± 0.04 1.40 ± 0.004 1.68 ± 0.007 1.44 ± 0.011
TPa dissolved (%) 1.58 ± 0.04 1.37 ± 0.05 1.54 ± 0.03 1.38 ± 0.004
40 ◦C (accelerated study)
pH 5.17 ± 0.03 4.93 ± 0.02 5.08 ± 0.03 4.92 ± 0.03
Redispersion time (s) 36.77 ± 1.26 8.33 ± 2.56 3.16 ± 0.23 2.00 ± 0.50
Viscosity (mPa s) 53.20 ± 1.99 8.61 ± 1.73 6.45 ± 0.18 9.84 ± 2.13
Zeta  potential -33.90 ± -33.90 -37.7 ± 4.65 -33.5 ± 5.79 -33.3 ± 5.41
TPa (mg/ml) 1.70 ± 0.04 1.46 ± 0.02 1.68 ± 0.007 1.47 ± 0.03
TPa dissolved (%)b 1.58 ± 0.04 1.37 ± 0.03 1.54 ± 0.03 1.32 ± 0.02
w
p
w
s
l
p
f
c
m
a
s
t
s
r
d
v
u
s
p
F
s
aa TP: total phenolic expressed in swertisin.
b Total phenolic dissolved in 10 min.
as small, the values were considered statistically different with
 < 0.05 in the analysis using F test at a signiﬁcance level of 5%.
The formulation containing CS (IX) did not showed settling
ithin 8 h, at the beginning and after 180 days. The formulations
howed an increase in the rate of settling during the study, i.e.,
ower sediment volume. This behaviour is related to the more com-
act cake formation over the storage period. However the sediment
ormed was easy to redisperse. As shown in Table 3, formulations
ontaining MCCS had faster rates of settling but also redispersed
ore easily. According to ANOVA analysis, formulation IX showed
 signiﬁcant difference in redispersion throughout the stability
tudy. This difference was conﬁrmed using the Tukey test between
he times 30, 90 and 180 days compared to zero time. During the
tability study, average viscosity was decreased (Table 3). These
esults are related to the behaviour of settling and redispersion,
ue to the lower viscosity, settling rate and faster redispersion.
The suspensions showed negative zeta potential (Table 3), with
alues below −30 mV,  that is resultant of anionic suspending agent
sed, and this condition remained until the end of the stability
tudy. Zeta potential values ± 30 mV  or more are considered appro-
riate for keeping the particles dispersed in the dispersion vehicle.
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ig. 2. Dissolution proﬁle of total phenolic (TP) from Aleurites moluccanus suspen-
ions  in different analyses conditions (medium and speed), using paddle apparatus
t  37 ◦C.The formulations showed a signiﬁcant decrease in total phe-
nolic assay at end of the stability study. The decrease was 14.11%
and 12.5% of total phenolic for formulations IX and X, respectively.
In this study, the total phenolic content expressed in swertisin
was employed as a parameter for monitoring the chemical stabil-
ity of the extract. Taking into account the complexity that is inhe-
rent in chemical extracts and consequently herbal medicine, this
variation is considered acceptable. Following Brazilian rules, the
allowed active marker variation during stability study for a phy-
tomedicine should be within ±15% (Anvisa, 2012). It is necessary
to evaluate other parameters/methods or applications of biologi-
cal activity assays in order to monitor more broadly the stability of
the extract (EMA, 2006). Furthermore, there are no chemical sta-
bility adjuvants, such as antioxidants, in the studied formulations.
Being an extract with high content of phenolic compounds, che-
mical degradation by oxidation can occur and the marker content
stability might increase with the addition of preservatives in the
formulation, such as antioxidants and chelating agents.
The stability study was  also accompanied by the dissolution
test of the suspensions at zero and 180 days. The proportion of TP
dissolved in 10 min  was determined. As shown in Table 3, the for-
mulations at time zero showed that more than 90% of TP dissolved
in 10 min. This result is similar to that obtained for the formulations
in the development stage.
Validation of the HPLC method
The analytical methods for total phenolic expressed in swertisin
for the assay and dissolution method were successfully validated
according to recommendations for the validation of analytical
methods (ICH, 2005; Anvisa, 2012).
The speciﬁcity of the method is shown in Fig. 3. In the chro-
matographic proﬁle of vehicle, only one peak was observed in
32 min; this same peak was found in the chromatographic proﬁle
of the suspension containing extract, but without interference in
retention time of peaks selected for quantiﬁcation of the pheno-
lic compounds present in the extracts (highlighted in Fig. 3). The
resolution (R) between the 2′′-O-ramnosilswertisin neighbour peak
was 1.595, and between swertisin and 2”-O-ramnosilswertisin was
1.384, showing that the principal peaks have R > 1.0; i.e.,  the method
provides adequate separation of these peaks.
The linearity of the method was determined for the pure extract
and the extract added to the suspension. The method was linear
from 0.5 to 5.0 mg/ml  (in dried extract) on both curves, with a cor-
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Fig. 3. Chromatography proﬁle of suspending vehicle (1); swertisin (2); suspension containing dry extract of Aleurites moluccanus (3) and dry extract of A. moluccanus (4) by
HPLC.
Table 4
Results of accuracy and precision of analytical method to assay of suspension containing Aleurites moluccanus dry extract.
Recovery
Theoretical TP
added (g/ml)
Practical TP
added (g/ml)
Recovery (%) Average (%) % RSD
19.26 22.34 116.00 103.13 10.82
32.10  30.83 90.06
44.94 43.74 97.34
Repeatability and Intermediary precisiona
Analyst 1 Analyst 2 Intermediary
precision
TP expressed in swertisin (mg/ml) 1.54 1.62 1.58
r
(
i
c
T
RRSD% 2.24 
a Analysis in 6 replicates.
elation coefﬁcient greater than 0.99. Also, the curves were parallel
slope of 2.1006), showing that there was no matrix interference
n the linearity of the quantiﬁcation method of TP in the range of
oncentrations analysed.
able 5
esults of analytical validation parameters of dissolution method of suspensions containi
Linearity
Intercept R Fcalc
−41,648.99 0.9967 1510.53 
Recov
Batches IX 
Theoretical TP
added (g/ml)
Practical TP added (g/ml) Recov
4.94 5.31 107
8.92  8.92 100
12.82 13.22 102
Average % 103.45 
RSD%  3.71 
Repeatability and inte
IX 
Analyst Interm
precis
1 2 
TP assay (mg/ml) 1.69 1.52 1.60
DPR%  2.96 2.54 7.48
a Analysis in 6 replicates.1.37 3.37
The analytical method showed accurate intra-assay results, with
an RSD% of 1.71% (Table 4). In the intermediate precision with
another analyst on at least 2 different days, the RSD% was  2.18%.
Assessing the intermediate precision, for two  days of analysis, the
ng Aleurites moluccanus dry extract.
Fcrit
2.12 × 10−07
ery
X
ery (%) Practical TP added
(g/ml)
Recovery (%)
.60 5.25 106.38
.01 9.15 102.58
.74 12.35 95.99
Average % 101.65
RSD% 5.16
rmediary precisiona
X
ediary
ion
Analyst Intermediary
precision
1 2
 1.65 1.53 1.59
 1.78 1.57 4.87
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ig. 4. Results of anti-inﬂammatory activity of suspensions containing Aleurites m
aline solution as negative control and indomethacin (10 mg/kg p.o.) as positive con
SD% was 3.05%, which was lower than that recommended by
NVISA, which is up to 15% for bioanalytical samples (Anvisa, 2012).
The average recovery of TP in the formulation IX was  103.1%
Table 4); therefore, this is within the range of 90 to 108% recom-
ended for concentrations between 1 and 10% (AOAC, 2012), when
onsidering that suspensions have 5% of dried extract.
The method was robust, with relatively low RSD% to changes
n temperature and ﬂow of the mobile phase. Although changes
ccurred in the retention time and resolution between the two
ain markers with ﬂow changes, the TP content showed no signi-
cant changes with small, deliberate changes in the method (data
ot shown).
The method was developed and selected for analysis of the dis-
olution proﬁle and the dissolution test of the suspensions of A.
oluccanus was validated following the recommendations of RE
99 (Anvisa, 2003). In this analysis, formulations IX and X were
sed.
The speciﬁcity of the dissolution method was assessed
y comparing the chromatograms of suspending vehicles,
uspensions containing dry extract and pure extract. Thenus dry extract using paw oedema induced by carrageenan (300 g/paw) in mice.
chromatogram proﬁles were similar to the assay method
(Fig. 3).
The results for the validation of the dissolution method are
shown in Table 5. The method was  linear from 0.24 to 0.82 mg/ml,
with a correlation coefﬁcient of 0.9967. The dissolution test was
precise for intra-assay variation, with an RSD% of 2.96% and 2.54%
for formulations IX and X, respectively. These were lower than the
maximum recommended by Anvisa, which is 5% and 15% for analyt-
ical and bioanalytical methods, respectively (Anvisa, 2003; 2012).
In intermediate precision with another analyst on at least 2 dif-
ferent days, the RSD was  1.78% and 1.57%, respectively, which is
also in accordance with the recommendations of ANVISA. Compar-
ing the two  tests, precision was obtained with an RSD% of 7.48%
and 4.87% for the formulations IX and X, respectively. The RSD of
7.48% is within that recommended by ANVISA of up to 15% (Anvisa,
2012), and is relatively high due to the heterogeneity in this dosage
form. The average recovery of formulations IX and X was  103.45%
and 101.65% respectively. These values are within the range rec-
ommended by the AOAC of 80–110% (AOAC, 2012). The LOQ for the
method was  0.143 mg/ml.
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nalysis of the pharmacological activity in vivo
The pharmacological experiments carried out with the for-
ulations IX and X validated the anti-inﬂammatory activity of
he dry standardised extract of A. moluccanus when administered
rally as a suspension. All formulations were able to signiﬁcantly
educe the paw oedema induced by carrageenan. Fig. 4 demon-
trates that the formulation IX (containing CS) showed a reduction
n paw oedema, with 35.5 ± 7.6% of inhibition. Otherwise, formu-
ation X (containing MCCS) did not interfere with the effects of
arrageenan in the mice paws. The positive-control drug used,
ndomethacin, was able to reduce paw-oedema, with an inhibition
f 54.8 ± 11%.
onclusion
The pharmaceutical suspensions containing 50 mg/ml of dry
xtract of A. moluccanus were obtained and physical and physical-
hemistry properties of formulations were appropriate and
haracteristic of the dosage forms. The use of carmellose sodium as
 suspending agent and sorbitol as a vehicle was important for the
rganoleptic and physical properties. The suspension-containing
xtract showed pharmacological activity observed in previous
tudies using extract only.
The analytical methods used in the assay and dissolution test
ere linear, accuracy, precise and selective for phenolic compounds
resent in the formulations.
The liquid dosage form developed can be used as an alternative
o tablets for the oral administration of new anti-inﬂammatory and
nalgesic herbal medicines.
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